Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, CCO, ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic ...

Pramorelin, also known in scientific literature as a synthetic ghrelin receptor agonist, has emerged as a notable peptide within the broader landscape of endocrine and metabolic research. Its primary ...

The explosion of biomedical data such as in genomics, structure biology and pharmacology can provide new opportunities to improve our understanding of human physiology and disease. Understanding the ...

Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...

New Cell-Based Assay Supports Drug Discovery Targeting Appetite Regulation, Stress Biology, and Autonomic Function ...

Nxera believes this is the best approach to maximise the value of the receptor program and enable it to reach patients. Nxera may also choose to participate in a Series A financing round of NewCo in ...

Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.